|Bid||0.0000 x 1400|
|Ask||0.0000 x 800|
|Day's Range||2.6881 - 2.8900|
|52 Week Range||2.2600 - 6.8700|
|Beta (3Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -10.34% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Biotechnology company Applied Genetic Technologies Corp (NASDAQ: AGTC ) presented interim six-month data Thursday for the Phase 1/2 XLRP program in X-linked retinitis pigmentosa, turning BMO Capital ...
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.